WO2019140417A1 - Aminopyridine based buffers with wide buffering ranges antibiotics and myelin disease therapy - Google Patents

Aminopyridine based buffers with wide buffering ranges antibiotics and myelin disease therapy Download PDF

Info

Publication number
WO2019140417A1
WO2019140417A1 PCT/US2019/013571 US2019013571W WO2019140417A1 WO 2019140417 A1 WO2019140417 A1 WO 2019140417A1 US 2019013571 W US2019013571 W US 2019013571W WO 2019140417 A1 WO2019140417 A1 WO 2019140417A1
Authority
WO
WIPO (PCT)
Prior art keywords
aminopyridine
salts
deacetylase inhibitor
amines
antibiotics
Prior art date
Application number
PCT/US2019/013571
Other languages
French (fr)
Inventor
Thomas P. Daly
Original Assignee
Daly Thomas P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/871,554 external-priority patent/US20180134662A1/en
Application filed by Daly Thomas P filed Critical Daly Thomas P
Publication of WO2019140417A1 publication Critical patent/WO2019140417A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/48—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring being part of a condensed ring system of the same carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/02—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C07C233/04—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C233/07—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having nitrogen atoms of carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals with carbon atoms of carboxamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring

Definitions

  • the present invention relates generally to the field of pyridine amines and more particularly to a classes of pyridine amines used as buffers in biological systems.
  • Amines are very useful compounds in the buffering of biological systems. Each class of amine has various limitations which require choosing an amine based on multiple factors to select the best amine. For example, pH buffering range is typically most important, but issues of chelation, and pH range stability, and solubility also come into play. Additionally, buffers interact with the biological system beyond simple buffering. The pyridine amines function to complex with cations in addition to buffering.
  • This property can be exploited to assist in pharmacological delivery systems, or as active pharmaceutical ingredients themselves.
  • the present invention relates to amines and amine derivatives that improve the buffering range, and / or contribute to chelation.
  • the reaction of amines or polyamines with various molecules to form polyamines with differing pKa’s will extend the buffering range, derivatives that result in polyamines that have the same pKa yields a greater buffering capacity.
  • Derivatives that result in zwitterionic buffers improve yield by allowing a greater range of stability.
  • Figs. 1A-1 B teach the synthesis of zwitterionic buffers derived from 3,4- aminopyridine.
  • Figs. 2A-2B show the derivation of zwitterionic buffers based on
  • Figs. 3A-3B teach the derivation of zwitterionic buffers from 2-aminopyridine, 3- aminopyridine, and 4-aminopyridine and aniline with 2-methyleneglutaric acid.
  • Figs. 4A-4B teach synthesis of phosphonates and sulfonates from 3,4- aminopyridine.
  • Figs. 5A-5B and Fig. 6A-6B show the synthesis of amides and carbamates from 3, 4-aminopyridine.
  • Figs. 7A-7B teach the synthesis of sulfonamides from 3, 4-aminopyridine.
  • Figs. 8A-8B teach the synthesis of dithiocarbamates from 3, 4-aminopyridine.
  • Figs. 9A-9B show the synthesis of alky amides of 3, 4-aminopyridine.
  • Figs. 10A-10B teach the synthesis of sulfonamides of 4-aminopyridine.
  • Figs. 11 -12 teach the synthesis of polyamides of 3, 4-aminopyridine.
  • amines with monochloroacetic acid (MCA)or sodium vinyl sulfonate (SVS) results in products are zwitterionic buffers that can buffer in both acidic and basic pH conditions.
  • a limited number amines are currently used for this purpose, such as, tromethamine and ammonia.
  • the further derivatization of the amines and polyamines with MCA and SVS yields a further crop of amine buffers with desirable properties.
  • MCA and sodium monochloroacetic acid can be used interchangeably.
  • the buffers taught herein, and their pharmacologically acceptable salts act as potassium channel blockers and many will behave as MAOI, monoamine oxidase inhibitors, making them potential therapeutic agents for demyelinating diseases, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other neurological disorders such as ALS.
  • MAOI monoamine oxidase inhibitors
  • Figures 1 and 2 teach the synthesis of zwitterionic buffers of 3,4-diaminopyridine.
  • Line i teaches the synthesis of a mono substitution on only one primary amino group.
  • Line ii teaches the synthesis where each primary amino group is mono-substituted to the secondary amine.
  • the tertiary amines can be formed.
  • the tertiary amines are simply the form where each primary amine group is di-substituted.
  • the Michael addition products need not be symmetric, where the Michael adduct is all the same.
  • the additions can be sequentially to make asymmetric products. The order of addition is such that one primary amino group reacts with the Michael adduct, then the second primary amine.
  • Figure 3 teaches the zwitterionic buffers of aminopyridines and 2- methyleneglutaric acid. These products act as potassium channel blockers, but are also expected to promote the generation of astrocytes, and thus greater neurological function.
  • Figure 4 teaches the synthesis of phosphonate and sulfonate buffers. As before, the figures only show the 1 : 1 molar reaction, but both reactive sites on the two primary amines may be reacted, yielding up to four sites. The simplest beyond the single mono substituted products are the disubstituted products where each amine group undergoes one addition to form the secondary amine. For the propane sultone product, the higher sultone analogs, such as butyl sultone are part of this invention as well.
  • Figure 5 teaches the synthesis of amides and carbamates that are useful as potassium channel blockers. Monethanol amine and diethanolamine analogues are taught and shown as symmetric additions. This need not be the case. Asymmetric additions are part of this invention.
  • Figure 6 expands on figure 5 to include a wider range of amides and carbamates. Again, while the figure shows a symmetric addition, asymmetric additions, where the constituent groups , A, D, E are not the same for the differnt nitrogens, are within the scope of this invention.
  • Figure 7 teaches the synthesis of sulfamides based in 3,4-aminopyridine.
  • Figure 8 teaches the synthesis of dithiocarbamates based on 3,4-aminopyridine.
  • caustic is shown as the basicity agent
  • any other basicity agent including, but not limited to other mineral bases, such as KOH, and tertiary amines methyldicoco amine is particularly useful as the resulting product exhibits much greater antimicrobial properties than the sodium or potassium derived forms. This is particularly interesting in agriculture and the methyldicoco amine acts as an adjuvant as well.
  • the figure shows the dithiocarbamates as free molecules, however, the free molecules are not stable and must be made and stored as the salts.
  • the representation as free molecules and not salts is to simplify the structure and to not limit the invention to any particular salt. One skilled in the art will recognize all salts as part of the invention.
  • Figure 9 teaches the addition of an acid chloride to form an amide group to the zwitterionic buffers.
  • the addition of the acid chloride to form the amide allows for the adjustment of water solubility and blood brain barrier penetration.
  • R is any alkyl chain, linear or branched, saturated or unsaturated, cyclic or acyclic.
  • a second, symmetric or asymmetric addition of acid chloride can be made to further enhance the shift in solubility. Also taught are less water soluble amides from aniline.
  • Figure 10 teaches sulfonamides from the sulfonates of Figure 7 and 4- aminopyridine.
  • the sulfonamides of the higher sulfonates from Figure 7 are also part of the invention as are the sulfonamides of 2-aminopyridine and 3-aminopyridine in place of 4-aminopyridine.
  • the analogous products where both primary amine groups of 3,4- diaminopyridine are reacted with either sodium vinyl sulfonate or a sultone to make the disulfonate of 3,4-diaminopyridine, can then be made into the corresponding
  • polyamides based on 3,4-diaminopyridine as well as aminopyridines in general.
  • the polyamides are expected to be potential treatments for cancer. The believed, but unconfirmed mode of action is thought to be histone deacetylase inhibition.

Abstract

Amines and amine derivatives that improve the buffering range, and / or reduce the chelation and other negative interactions of the buffer and the system to be buffered. Aminopyridines channel blocking, combined with buffering and zwitterionic charge states make promising therapies for myelin diseases.

Description

Aminopyridine Based Buffers with Wide Buffering Ranges Antibiotics and Myelin
Disease Therapy
BACKGROUND
Field of the Invention
The present invention relates generally to the field of pyridine amines and more particularly to a classes of pyridine amines used as buffers in biological systems.
Description of the Problem Solved by the Invention
Amines are very useful compounds in the buffering of biological systems. Each class of amine has various limitations which require choosing an amine based on multiple factors to select the best amine. For example, pH buffering range is typically most important, but issues of chelation, and pH range stability, and solubility also come into play. Additionally, buffers interact with the biological system beyond simple buffering. The pyridine amines function to complex with cations in addition to buffering.
This property can be exploited to assist in pharmacological delivery systems, or as active pharmaceutical ingredients themselves.
SUMMARY OF THE INVENTION
The present invention relates to amines and amine derivatives that improve the buffering range, and / or contribute to chelation. The reaction of amines or polyamines with various molecules to form polyamines with differing pKa’s will extend the buffering range, derivatives that result in polyamines that have the same pKa yields a greater buffering capacity. Derivatives that result in zwitterionic buffers improve yield by allowing a greater range of stability.
DESCRIPTION OF THE FIGURES
Attention is now directed to the following figures that describe embodiments of the present invention:
Figs. 1A-1 B teach the synthesis of zwitterionic buffers derived from 3,4- aminopyridine.
Figs. 2A-2B show the derivation of zwitterionic buffers based on
monochloroacetic acid and longer chain acrylates.
Figs. 3A-3B teach the derivation of zwitterionic buffers from 2-aminopyridine, 3- aminopyridine, and 4-aminopyridine and aniline with 2-methyleneglutaric acid. Figs. 4A-4B teach synthesis of phosphonates and sulfonates from 3,4- aminopyridine.
Figs. 5A-5B and Fig. 6A-6B show the synthesis of amides and carbamates from 3, 4-aminopyridine.
Figs. 7A-7B teach the synthesis of sulfonamides from 3, 4-aminopyridine.
Figs. 8A-8B teach the synthesis of dithiocarbamates from 3, 4-aminopyridine. Figs. 9A-9B show the synthesis of alky amides of 3, 4-aminopyridine.
Figs. 10A-10B teach the synthesis of sulfonamides of 4-aminopyridine.
Figs. 11 -12 teach the synthesis of polyamides of 3, 4-aminopyridine.
Several drawings and illustrations have been presented to aid in understanding the invention. The scope of the present invention is not limited to what is shown in the figures.
DETAILED DESCRIPTION OF THE INVENTION
Combining amines with monochloroacetic acid (MCA)or sodium vinyl sulfonate (SVS) results in products are zwitterionic buffers that can buffer in both acidic and basic pH conditions. A limited number amines are currently used for this purpose, such as, tromethamine and ammonia. The reaction of amines, alcohols, and aminoalcohols with acrylonitrile (via the Michaels Addition), followed by reduction results in amines and polyamines that have a broad buffering range. The further derivatization of the amines and polyamines with MCA and SVS yields a further crop of amine buffers with desirable properties. One skilled in the art will recognize that MCA and sodium monochloroacetic acid (SMCA) can be used interchangeably. Furthermore, the buffers taught herein, and their pharmacologically acceptable salts, act as potassium channel blockers and many will behave as MAOI, monoamine oxidase inhibitors, making them potential therapeutic agents for demyelinating diseases, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other neurological disorders such as ALS. Furthermore, several molecules taught here as part of this invention are expected to promote the formation of astrocytes. Astrocytes are a key component of maintaining function and healing of spinal cord injuries, particularly those that result in a less than complete severing of the spinal cord, but that result in a removal of myelin from part of the neuron. In this case, the potassium ions that propagate the action potential are able to leak out of the neuron.
The use of a potassium channel blocker, such as those taught here, along with an astrocyte promoter greatly improves neural function. Figures 1 and 2 teach the synthesis of zwitterionic buffers of 3,4-diaminopyridine.
Line i teaches the synthesis of a mono substitution on only one primary amino group. Line ii teaches the synthesis where each primary amino group is mono-substituted to the secondary amine. By utilizing HCI and methanol as the reaction media, the tertiary amines can be formed. The tertiary amines are simply the form where each primary amine group is di-substituted. The Michael addition products need not be symmetric, where the Michael adduct is all the same. The additions can be sequentially to make asymmetric products. The order of addition is such that one primary amino group reacts with the Michael adduct, then the second primary amine. Adding HCI and methanol, then adding a third equivalent of a Michael adduct will form a tertiary amine to one of the original primary amines, and finally the last amino hydrogen will react to from the only tertiary amine containing product. While not generally explicitly shown in subsequent figures, this principle holds throughout the invention disclosure.
Figure 3 teaches the zwitterionic buffers of aminopyridines and 2- methyleneglutaric acid. These products act as potassium channel blockers, but are also expected to promote the generation of astrocytes, and thus greater neurological function. Figure 4 teaches the synthesis of phosphonate and sulfonate buffers. As before, the figures only show the 1 : 1 molar reaction, but both reactive sites on the two primary amines may be reacted, yielding up to four sites. The simplest beyond the single mono substituted products are the disubstituted products where each amine group undergoes one addition to form the secondary amine. For the propane sultone product, the higher sultone analogs, such as butyl sultone are part of this invention as well.
Figure 5 teaches the synthesis of amides and carbamates that are useful as potassium channel blockers. Monethanol amine and diethanolamine analogues are taught and shown as symmetric additions. This need not be the case. Asymmetric additions are part of this invention. Figure 6 expands on figure 5 to include a wider range of amides and carbamates. Again, while the figure shows a symmetric addition, asymmetric additions, where the constituent groups , A, D, E are not the same for the differnt nitrogens, are within the scope of this invention. Figure 7 teaches the synthesis of sulfamides based in 3,4-aminopyridine.
Figure 8 teaches the synthesis of dithiocarbamates based on 3,4-aminopyridine.
While caustic is shown as the basicity agent, any other basicity agent may be used, including, but not limited to other mineral bases, such as KOH, and tertiary amines methyldicoco amine is particularly useful as the resulting product exhibits much greater antimicrobial properties than the sodium or potassium derived forms. This is particularly interesting in agriculture and the methyldicoco amine acts as an adjuvant as well. The figure shows the dithiocarbamates as free molecules, however, the free molecules are not stable and must be made and stored as the salts. The representation as free molecules and not salts is to simplify the structure and to not limit the invention to any particular salt. One skilled in the art will recognize all salts as part of the invention.
Figure 9 teaches the addition of an acid chloride to form an amide group to the zwitterionic buffers. The addition of the acid chloride to form the amide allows for the adjustment of water solubility and blood brain barrier penetration. R is any alkyl chain, linear or branched, saturated or unsaturated, cyclic or acyclic. A second, symmetric or asymmetric addition of acid chloride can be made to further enhance the shift in solubility. Also taught are less water soluble amides from aniline.
Figure 10 teaches sulfonamides from the sulfonates of Figure 7 and 4- aminopyridine. The sulfonamides of the higher sulfonates from Figure 7 are also part of the invention as are the sulfonamides of 2-aminopyridine and 3-aminopyridine in place of 4-aminopyridine. The analogous products where both primary amine groups of 3,4- diaminopyridine are reacted with either sodium vinyl sulfonate or a sultone to make the disulfonate of 3,4-diaminopyridine, can then be made into the corresponding
disulfonamide with either 2-aminopyridine, 3-aminopyridine, 4-aminopyridine, 3,4- diaminopyridine or any combination thereof. Figures 11 -12 teach a series of
polyamides based on 3,4-diaminopyridine as well as aminopyridines in general. The polyamides are expected to be potential treatments for cancer. The believed, but unconfirmed mode of action is thought to be histone deacetylase inhibition.
Several descriptions and illustrations have been presented to enhance
understanding of the present invention. One skilled in the art will know that numerous changes and variations are possible without departing from the spirit of the invention. Each of these changes and variations are within the scope of the present invention.

Claims

Claims
Claim 1 . A histone deacetylase inhibitor of the following structure:
Figure imgf000008_0001
where A, A and A" are independently chosen from -H or -NH3, X, X, X", Y, Y, Y", Z, Z', Z" are independently chosen from C or N such that only 1 of X, Y or Z is N; only 1 of X, Y, or Z' is N; and only 1 of X", Y", or Z" is N, where n is a non-negative integer.
Claim 2. The histone deacetylase inhibitor of the following structure:
Figure imgf000008_0002
where, X, Y, and Z are selected from C or N where only one of X,Y, or Z may be N, m is an integer from 2-5.
Claim 3. The histone deacetylase inhibitor and its salts of claim 2 where Z=N, X=Y=C.
Claim 4. The deacetylase inhibitor and its salts of claim 3 where m=2.
Claim 5. The deacetylase inhibitor and its salts of claim 3 where m=3.
Claim 6. The deacetylase inhibitor and its salts of claim 3 where m=4
Claim 7. The deacetylase inhibitor and its salts of claim 3 where m=5
Claim 8. The histone deacetylase inhibitor and its salts of claim 2 where X=N, Y=Z=C.
Claim 8. The deacetylase inhibitor and its salts of claim 8 where m=1.
Claim 9. The deacetylase inhibitor and its salts of claim 8 where m=2.
Claim 10. The deacetylase inhibitor and its salts of claim 8 where m=3.
Claim 11. The deacetylase inhibitor and its salts of claim 8 where m=4.
Claim 12. The deacetylase inhibitor and its salts of claim 8 where m=5.
Claim 13. The histone deacetylase inhibitor and its salts of claim 2 where Y=N, X=Z=C.
Claim 14. The deacetylase inhibitor and its salts of claim 13 where m=1.
Claim 15. The deacetylase inhibitor and its salts of claim 13 where m=2.
Claim 16. The deacetylase inhibitor and its salts of claim 13 where m=3.
Claim 17. The deacetylase inhibitor and its salts of claim 13 where m=4.
Claim 18. The deacetylase inhibitor and its salts of claim 13 where m=5.
PCT/US2019/013571 2018-01-15 2019-01-15 Aminopyridine based buffers with wide buffering ranges antibiotics and myelin disease therapy WO2019140417A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15/871,554 US20180134662A1 (en) 2015-11-17 2018-01-15 Aminopyridine Based Buffers with Wide Buffering Ranges Antibiotics and Myelin Disease Therapy
US15/871,554 2018-01-15

Publications (1)

Publication Number Publication Date
WO2019140417A1 true WO2019140417A1 (en) 2019-07-18

Family

ID=67218706

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/013571 WO2019140417A1 (en) 2018-01-15 2019-01-15 Aminopyridine based buffers with wide buffering ranges antibiotics and myelin disease therapy

Country Status (1)

Country Link
WO (1) WO2019140417A1 (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031977A1 (en) * 1994-05-19 1995-11-30 Sloan-Kettering Institute For Cancer Research Novel potent inducers of terminal differentiation and methods of use thereof
US6277854B1 (en) * 1996-09-13 2001-08-21 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
WO2003032921A2 (en) * 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US20050107355A1 (en) * 2003-11-14 2005-05-19 Dolle Roland E. Amide derivatives and methods of their use
WO2005053610A2 (en) * 2003-11-26 2005-06-16 Aton Pharma, Inc. Diamine and iminodiacetic acid hydroxamic acid derivatives
WO2006017216A1 (en) * 2004-07-12 2006-02-16 Merck & Co., Inc. Histone deacetylase inhibitors
WO2007058927A1 (en) * 2005-11-11 2007-05-24 The Scripps Research Institute Histone deacetylase inhibitors as therapeutics for neurological diseases
WO2008090585A2 (en) * 2007-01-26 2008-07-31 Università Degli Studi Di Roma La Sapienza Soluble forms of inclusion complexes of histone deacetylase inhibitors and cyclodextrins, their preparation processes and uses in the pharmaceutical field
EP2824108A1 (en) * 2012-03-06 2015-01-14 Tianjin Hemay Bio-Tech Co., Ltd. Tetracyclic anthraquinone derivatives

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995031977A1 (en) * 1994-05-19 1995-11-30 Sloan-Kettering Institute For Cancer Research Novel potent inducers of terminal differentiation and methods of use thereof
US6277854B1 (en) * 1996-09-13 2001-08-21 Schering Corporation Tricyclic antitumor farnesyl protein transferase inhibitors
WO2003032921A2 (en) * 2001-10-16 2003-04-24 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases and cancer of the brain
US20050107355A1 (en) * 2003-11-14 2005-05-19 Dolle Roland E. Amide derivatives and methods of their use
WO2005053610A2 (en) * 2003-11-26 2005-06-16 Aton Pharma, Inc. Diamine and iminodiacetic acid hydroxamic acid derivatives
WO2006017216A1 (en) * 2004-07-12 2006-02-16 Merck & Co., Inc. Histone deacetylase inhibitors
WO2007058927A1 (en) * 2005-11-11 2007-05-24 The Scripps Research Institute Histone deacetylase inhibitors as therapeutics for neurological diseases
WO2008090585A2 (en) * 2007-01-26 2008-07-31 Università Degli Studi Di Roma La Sapienza Soluble forms of inclusion complexes of histone deacetylase inhibitors and cyclodextrins, their preparation processes and uses in the pharmaceutical field
EP2824108A1 (en) * 2012-03-06 2015-01-14 Tianjin Hemay Bio-Tech Co., Ltd. Tetracyclic anthraquinone derivatives

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DOLZHENKO A.V. ET AL.: "Substituted amides and hydrazides of dicarboxylic acids. Part 11. Synthesis and pharmacological activity of a series of pyridylamides of dicarboxylic acids", PHARMACEUTICAL CHEMISTRY JOURNAL, vol. 36, no. 23, 2002, pages 125 - 126, XP055624608 *
EVANS D.W.S. ET AL.: "Synthesis of potential antibacterial agents. III. Derivatives of some a,a'-dialkylglutaric acids", JOURNAL OF THE CHEMICAL SOCIETY, 1957, pages 2104 - 2106, XP055624611, DOI: 10.1039/JR9570002104 *
MNDZHOYAN A.L. ET AL.: "Derivatives of dibasic carboxylic acids. XVI. 2-Pyridyl- and 4-methyl-2-thiazolylamides of dibasic carboxylic acids", DOKLADY AKADEMII NAUK ARMYANSKOI SSR, vol. 22, 1956, pages 215 - 219 *
NISONOFF ALFRED ET AL.: "Annular nitrogen of pyridine as a determinant of immunological specificity", JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 79, no. 20, 1957, pages 5565 - 5572, XP055624607 *

Similar Documents

Publication Publication Date Title
DE69827940T2 (en) THIARYLSULFONAMID-hydroxamic acid
US10844080B2 (en) Compositions and methods for inhibiting arginase activity
CA2299355C (en) Aryloxyarylsulfonylamino hydroxamic acid derivatives
EP2208721B1 (en) Histone deacetylase inhibitor, composition and use thereof
TW474909B (en) Aniline derivatives possessing an inhibitory effect of nitric oxide synthase
CA2458035A1 (en) Quaternary ammonium salts of omega-aminoalkylamides of r-2-aryl-propionic acids and pharmaceutical compositions containing them
CA2258850A1 (en) Il-8 receptor antagonists
JP2008500392A5 (en)
EP0725059A1 (en) 2,3-diaminopropionic acid derivative
US9676818B2 (en) Toll-like receptor 2-agonistic lipopeptides, and method of making the same
AU2011203743A1 (en) Anti-heparin compounds
WO2019140417A1 (en) Aminopyridine based buffers with wide buffering ranges antibiotics and myelin disease therapy
US8497398B1 (en) Polyamine transporter selective compounds as anti-cancer agents
US20180134662A1 (en) Aminopyridine Based Buffers with Wide Buffering Ranges Antibiotics and Myelin Disease Therapy
CA2657316A1 (en) Method for improving pharmacokinetics
US9867813B2 (en) Aminopyridine based buffers with wide buffering ranges, antibiotics and myelin disease therapy
PT88004B (en) SUBSTITUTED GUANIDINES, CONTAINING A TETRAZOLE PORN, UTEIS AS HIGH-PURPOSE SWEETENING AGENTS
Park et al. Design and synthesis of butynyloxyphenyl β-sulfone piperidine hydroxamates as TACE inhibitors
US9090638B2 (en) Biological buffers with wide buffering ranges
JP2022538074A (en) Compounds, compositions and methods for protein degradation
US2781389A (en) Detergent sulphonic acid and sulphate salts of certain amphoteric detergents
CA2484671A1 (en) Cyanoguanidine prodrugs
US20190233372A1 (en) Carbondisulfide Derived Zwitterions
US20210246344A1 (en) Biological buffers with wide buffering ranges
BRPI0415295A (en) process for the production of trans- or cisdiamÈniodichlorodihydroxiplatin (iv) and its use for the production of pharmaceutical agent

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19738650

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19738650

Country of ref document: EP

Kind code of ref document: A1